Imagion Biosystems Limited
IBXXF
$0.01
-$0.025-71.43%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -46.15% | 0.93% | 64.95% | 61.12% | 57.40% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -46.15% | 0.93% | 64.95% | 61.12% | 57.40% |
| Cost of Revenue | -92.41% | -60.15% | -19.16% | 7.98% | 38.53% |
| Gross Profit | 788.34% | 619.76% | 536.69% | 277.02% | 50.58% |
| SG&A Expenses | -74.74% | -52.02% | -27.99% | -4.53% | 23.57% |
| Depreciation & Amortization | -67.16% | -42.64% | -18.73% | -8.80% | 2.28% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -79.74% | -53.72% | -24.81% | -1.38% | 25.98% |
| Operating Income | 93.72% | 73.62% | 52.76% | 20.72% | -16.31% |
| Income Before Tax | 83.63% | 66.05% | 47.70% | 16.23% | -21.32% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 83.63% | 66.05% | 47.70% | 16.23% | -21.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 83.63% | 66.05% | 47.70% | 16.23% | -21.32% |
| EBIT | 93.72% | 73.62% | 52.76% | 20.72% | -16.31% |
| EBITDA | 97.41% | 78.36% | 58.60% | 25.66% | -12.49% |
| EPS Basic | 86.72% | 70.77% | 55.07% | 23.39% | -14.37% |
| Normalized Basic EPS | 86.78% | 70.82% | 55.09% | 23.38% | -14.33% |
| EPS Diluted | 86.72% | 70.77% | 55.07% | 23.39% | -14.37% |
| Normalized Diluted EPS | 86.78% | 70.82% | 55.09% | 23.38% | -14.33% |
| Average Basic Shares Outstanding | 47.45% | 32.64% | 16.54% | 12.64% | 8.75% |
| Average Diluted Shares Outstanding | 47.45% | 32.64% | 16.54% | 12.64% | 8.75% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
